STEP III: budgetary impact analysis
This entails looking at the impact of the use of the agents in a therapeutic class on the complete healthcare economy that is both primary and secondary care. This is of key importance, as the product selection is to inform a joint formulary to yield safe and cost-effective therapy for the population. To compare the agents in a therapeutic class, the overall usage was profiled into defined daily doses (DDD).
